Latest news
Trevi Therapeutics (TRVI) Starts Key Cough Trials, Is It Still 29% Below Fair Value? - SahmSahm · Sat, 08 Aug 2026 19:09:24 GMTOppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $25 - MoomooMoomoo · Sat, 08 Aug 2026 07:14:59 GMTTrevi Therapeutics (NASDAQ:TRVI) Announces Earnings Results, Hits Estimates - MarketBeatMarketBeat · Fri, 07 Aug 2026 23:12:38 GMTTRVI Aug 2026 22.000 call (TRVI260821C00022000) interactive stock chart - Yahoo Finance AustraliaYahoo Finance Australia · Fri, 07 Aug 2026 19:15:20 GMTTrevi Therapeutics Q2 Earnings Call Highlights - TradingViewTradingView · Fri, 07 Aug 2026 18:04:23 GMTTrevi Therapeutics, Inc. Stock 12‑Month Price Target Raised to $29.17, Implies 58% Upside - TradingViewTradingView · Fri, 07 Aug 2026 17:20:32 GMTTRVI Maintains Rating by Oppenheimer -- Price Target Raised to $25.00 - GuruFocusGuruFocus · Fri, 07 Aug 2026 16:47:42 GMTTRVI Aug 2026 17.000 call (TRVI260821C00017000) Interactive Stock Chart - Yahoo! Finance CanadaYahoo! Finance Canada · Fri, 07 Aug 2026 15:24:45 GMT